COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of of APL-2 Therapy in Patients Geographic Atrophy (FILLY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02503332
Recruitment Status : Completed
First Posted : July 20, 2015
Last Update Posted : November 19, 2019
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : January 11, 2018
Actual Study Completion Date : January 11, 2018
Certification/Extension First Submitted : November 13, 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 4, 2020
August 19, 2020
2 September 14, 2020